News
February 11, 2021
FDA Approves First-in-class Evkeeza™ (evinacumab-dgnb) for Patients with Ultra-rare Inherited Form of High Cholesterol
Regeneron Pharmaceuticals, Inc. announced that the U.S. Food and Drug Administration (FDA) approved EvkeezaTM...
Read More...January 15, 2021
NLA & Chapter Nomination Windows Open Through February 28, 2021
The window for nominations to NLA and Chapter leadershp positions is now open through February 28, 2021. Open positions...
Read More...January 6, 2021
National Lipid Association Achieves New Six Year Term for Joint Accreditation
JACKSONVILLE, Fla. – (January 6, 2021) -- The National Lipid Association (NLA) is proud to announce that it has...
Read More...December 12, 2020
NLA Releases Official Scientific Statement on CAC Scoring
The NLA today announced the release of its official scientific statement on CAC scoring to guide prevention of ASCVD.
Read More...December 10, 2020
National Lipid Association Announces Late-Breaking Abstract Presentations at NLA 2020 Virtual Scientific Sessions
National Lipid Association Announces Late-Breaking Abstract Presentations at NLA 2020 Virtual Scientific Sessions...
Read More...